IMDC Risk Model for Metastatic Renal Cell Carcinoma

Predicts survival in patients with metastatic renal cell carcinoma treated with systemic therapy (also known as Heng criteria).

<1 year from time of diagnosis to systemic therapy

Karnofsky Performance Status <80%

Hemoglobin < lower limit of normal

  • Usually ~120 g/L or 12 g/dL

Corrected calcium > upper limit of normal

  • Usually ~120 g/L or 12 g/dL

Neutrophils > upper limit of normal

  • Usually ~2.0-7.0ₓ109/L

Platelets > upper limit of normal

  • Usually ~150,000-400,000 cells/µL

Interpretation

Source: Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. JCO. Dec 1, 2009:5794-5799; published online on October 13, 2009.
Copy Results Reset Print